- Home
- CBIO vs RFMZ Comparison
CBIO vs RFMZ Comparison
Compare CBIO & RFMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- RFMZ
- Stock Information
- Founded
- CBIO 2003
- RFMZ 2021
- Country
- CBIO United States
- RFMZ United States
- Employees
- CBIO N/A
- RFMZ N/A
- Industry
- CBIO
- RFMZ Trusts Except Educational Religious and Charitable
- Sector
- CBIO
- RFMZ Finance
- Exchange
- CBIO Nasdaq
- RFMZ Nasdaq
- Market Cap
- CBIO 308.0M
- RFMZ 310.1M
- IPO Year
- CBIO N/A
- RFMZ N/A
- Fundamental
- Price
- CBIO $14.29
- RFMZ $12.54
- Analyst Decision
- CBIO Strong Buy
- RFMZ
- Analyst Count
- CBIO 5
- RFMZ 0
- Target Price
- CBIO $25.60
- RFMZ N/A
- AVG Volume (30 Days)
- CBIO 98.3K
- RFMZ 76.6K
- Earning Date
- CBIO 07-31-2025
- RFMZ 01-01-0001
- Dividend Yield
- CBIO N/A
- RFMZ 7.43%
- EPS Growth
- CBIO N/A
- RFMZ N/A
- EPS
- CBIO N/A
- RFMZ 0.65
- Revenue
- CBIO N/A
- RFMZ N/A
- Revenue This Year
- CBIO N/A
- RFMZ N/A
- Revenue Next Year
- CBIO N/A
- RFMZ N/A
- P/E Ratio
- CBIO N/A
- RFMZ $21.49
- Revenue Growth
- CBIO N/A
- RFMZ N/A
- 52 Week Low
- CBIO $10.83
- RFMZ $11.28
- 52 Week High
- CBIO $21.40
- RFMZ $14.57
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- RFMZ 44.54
- Support Level
- CBIO $13.50
- RFMZ $12.45
- Resistance Level
- CBIO $16.00
- RFMZ $12.61
- Average True Range (ATR)
- CBIO 0.79
- RFMZ 0.13
- MACD
- CBIO 0.16
- RFMZ -0.02
- Stochastic Oscillator
- CBIO 39.68
- RFMZ 13.24
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.